TG Therapeutics Inc. (TGTX)
NASDAQ: TGTX
· Real-Time Price · USD
27.71
-0.37 (-1.32%)
At close: Aug 18, 2025, 3:59 PM
27.79
0.27%
After-hours: Aug 18, 2025, 07:20 PM EDT
-1.32% (1D)
| Bid | 24.08 |
| Market Cap | 4.4B |
| Revenue (ttm) | 454.07M |
| Net Income (ttm) | 60.46M |
| EPS (ttm) | 0.38 |
| PE Ratio (ttm) | 72.93 |
| Forward PE | 15.51 |
| Analyst | Buy |
| Ask | 31.88 |
| Volume | 2,012,170 |
| Avg. Volume (20D) | 2,008,232 |
| Open | 28.30 |
| Previous Close | 28.08 |
| Day's Range | 27.71 - 28.83 |
| 52-Week Range | 21.11 - 46.48 |
| Beta | 1.95 |
About TGTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TGTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TGTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
TG Therapeutics Inc. is scheduled to release its earnings on
Nov 3, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-17.99%
TG Therapeutics shares are trading lower after the...
Unlock content with
Pro Subscription
3 months ago
-13.26%
TG Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.
2 weeks ago · fool.com
TG Therapeutics Q2 Revenue Up 91%TG Therapeutics Q2 Revenue Up 91%
1 month ago · seekingalpha.com
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-CelTG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY to $119.7M, driven by strong U.S. growth. A subcutaneous version of TGTX's BRIUMVI is in phase 1 trials, with late-stage development ...
